|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Oct 19, 2009. Dublin, Ireland; South San Francisco
– October 19, 2009 – Elan Corporation, plc (NYSE: ELN) and Biogen Idec
(NASDQ: BIIB) today announced multiple presentations at the American College of
Gastroenterology (ACG) Annual Scientific Meeting, taking place October 23-28 in
San Diego.
The
posters and presentations during ACG will highlight TYSABRI®
(natalizumab) data in treating Crohn’s Disease. During a plenary session on
inflammatory bowel disease (IBD), an oral presentation will focus on a
retrospective subset analysis of two registrational Phase 3 trials (ENACT-2
[Evaluation of Natalizumab as Continuous Therapy] and ENCORE [Efficacy of
Natalizumab in Crohn’s Disease Response and Remission]) and one open-label study
(ENABLE). Corey A. Siegel, MD, director of the Inflammatory Bowel Disease (IBD)
Center at Dartmouth-Hitchcock Medical Center will give the presentation. In
addition, representatives from Elan and investigators will present four posters
that analyze patient reported outcomes from the TOUCH study, and one poster
reporting the utilization and safety results from the TOUCH™ prescribing and
surveillance program.
Details
of the presentations at ACG are as follows:
* Note:
All times are listed in Pacific Time
Sunday,
October 25:
Abstract
P270: 3:30 - 7:00 PM 1
Abstract
P271: 3:30 - 7:00 PM
Monday,
October 26:
Abstract
P724: 12:15 - 2:00 PM
Tuesday,
October 27:
Abstract
P1100: 12:15 - 2:00 PM
Abstract
P1104: 12:15 - 2:00 PM
Abstract
41: 2:45 – 4:15 PM
About
Crohn's Disease
An
estimated 500,000 people in the United States have Crohn's disease, a chronic
and progressive inflammatory disease of the gastrointestinal tract, which
commonly affects both men and women.
The
disease usually causes diarrhea and crampy abdominal pain, often associated with
fever, and at times rectal bleeding. Loss of appetite and weight loss also may
occur. Complications include narrowing of the intestine, obstruction, abscesses,
and fistulas (abnormal channels connecting the intestine and other organs,
including the skin), and malnutrition. Most patients eventually require surgery,
which has both risks and potential short- and long-term
complications.
Crohn's
disease can have a devastating impact on the lifestyle of patients, many of whom
are young and active. Currently there is no medical or surgical cure for Crohn's
disease. Many patients fail to respond to current therapies, including
biological therapies such as agents that inhibit tumor necrosis factor alpha
(TNF-alpha). Due to this failure of current therapies in CD, therapies that have
alternate biological targets may provide patients and physicians with other
therapeutic options.
|
| |||||||
